Nachhaltig leben. lernen. forschen

Medizinische Universität Graz

Clinical Trials

Acute myeloid leukemia

AMLSG BiO Registry Study on Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Acute Leukemias of Ambiguous Lineage
AMLSG 21-13 Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML), AMLSG 21-13
2012-003457-28 A phase-3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral Azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission
2014-001233-89   A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
2015-000344-42 A phase 3, multicenter open-label, randomized study comparing the efficacy and safety of AG-221(CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation
2014-003065-15 A multicenter, double-blind, randomized, placebo-controlled, phase III study of RO5503781, an MDM2 antagonist, with cytarabine versus cytarabine plus placebo in patients with relapsed or refractory acute myeloid leukemia (AML)
2015-003596-30 A randomized, multicenter, open-label, phase 2 study evaluating the efficacy and safety of azacitidine subcutaneous in combination with durvalumab (MEDI4736) in previously untreated subjects with higher-risk myelodysplastic syndromes (MDS) or in elderly (≥ 65 years) acute myeloid leukemia (AML) subjects not eligibile for hematopoietic stem cell transplantation (HSCT)

Chronic myeloid leukemia

2012-005124-15 A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID
2012-004092-40 A single arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment
2011-006181-41   An open label, randomized (2:1)phase 2B study of dasatinib vs. imatinib in patients with chronic phase chronic myeloid leukemia who have nit achieved an optimal response to 3 month of therapy with 400 MG imatinib
2015-001318-92 A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
  • TEXT
  • TEXT
  • TEXT
  • TEXT